Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An in vivo platform for translational drug development in pancreatic cancer.
Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M. Rubio-Viqueira B, et al. Among authors: cusatis g. Clin Cancer Res. 2006 Aug 1;12(15):4652-61. doi: 10.1158/1078-0432.CCR-06-0113. Clin Cancer Res. 2006. PMID: 16899615
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Jimeno A, et al. Among authors: cusatis g. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24. Oncogene. 2009. PMID: 19029951 Free PMC article.
Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer.
Jimeno A, Hallur G, Chan A, Zhang X, Cusatis G, Chan F, Shah P, Chen R, Hamel E, Garrett-Mayer E, Khan S, Hidalgo M. Jimeno A, et al. Among authors: cusatis g. Mol Cancer Ther. 2007 May;6(5):1509-16. doi: 10.1158/1535-7163.MCT-06-0592. Epub 2007 May 4. Mol Cancer Ther. 2007. PMID: 17483439
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD. Cusatis G, et al. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42. doi: 10.1093/jnci/djj469. J Natl Cancer Inst. 2006. PMID: 17148776
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A. Lepper ER, et al. Among authors: cusatis g. Clin Cancer Res. 2005 Oct 15;11(20):7398-404. doi: 10.1158/1078-0432.CCR-05-0520. Clin Cancer Res. 2005. PMID: 16243813 Clinical Trial.
17 results